返回 
加入收藏
妥布霉素地塞米松治疗睑板腺功能障碍的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 妥布霉素地塞米松治疗睑板腺功能障碍的临床观察 |
| TITLE： | |
| 摘要： | 目的： 观察妥布霉素地塞米松治疗睑板腺功能障碍（MGD）的疗效和安全性。方法：108例MGD患者随机分为对照组（53例）和观察组（55例）。对照组患者给予常规物理清洁方式清理眼睑，同时饭后温水送服盐酸多西环素片0.1 g，每日2次。观察组患者在对照组治疗的基础上给予妥布霉素地塞米松眼膏长约1.0～1.5 cm，涂入结膜囊，每日4次。两组疗程均为4周。观察两组患者的临床疗效，治疗前后眼睑观察评分、症状评分、白细胞介素6（IL-6）和肿瘤坏死因子α（TNF-α ）水平及不良反应发生情况。结果： 观察组患者总有效率显著高于对照组（89.1％ vs. 77.4％），差异有统计学意义（P＜0.05）。治疗前，两组患者眼睑观察评分、症状评分、IL-6和TNF-α水平比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者眼睑观察评分均显著高于同组治疗前，且观察组显著高于对照组；两组患者症状评分、IL-6和TNF-α水平均显著低于同组治疗前，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论： 在常规治疗的基础上给予妥布霉素地塞米松治疗MGD患者的疗效显著，可显著改善临床症状，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of tobramycin dexamethasone in the treatment of meibomian gland dysfunction （MGD）. METHODS： 108 MGD patients were randomly divided into control group （53 cases） and observation group （55 cases）. Control group was given eyelid cleaning with conventional physical cleaning method， at the same time， given Doxycycline hydrochloride tablets 0.1 g orally after meal， twice a day. Based on control group， observation group was additionally given Tobramycin and dexamethasone eye ointment with length of 1.0-1.5 cm， smearing into conjunctival sac， 4 times a day. Treatment courses of 2 groups lasted for 4 weeks. Clinical efficacies of 2 groups were observed as well as eyelid observation score， symptom score， the levels of IL-6 and TNF-α， the occurrence of ADR before and after treatment. RESULTS： The total response rate of observation group was significantly higher than that of control group（89.1％ vs. 77.4％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in eyelid observation score， symptom score， the levels of IL-6 and TNF-α between 2 groups （P＞0.05）. After treatment， eyelid observation score of 2 groups were significantly higher than before treatment， and the observation group was significantly higher than the control group； symptom score and the levels of IL-6 and TNF-α in 2 groups were significantly lower than before treatment， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）.There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Based on routine treatment， tobramycin dexamethasone shows significant therapeutic efficacy for MGD， and can improve clinical symptoms significantly but does not increase the occurrence of ADR. |
| 期刊： | 2017年第28卷第15期 |
| 作者： | 丁剑锋，罗远湘，李璐 |
| AUTHORS： | DING Jianfeng，LUO Yuanxiang，LI Lu |
| 关键字： | 妥布霉素地塞米松；睑板腺功能障碍；疗效；安全性；白细胞介素6；肿瘤坏死因子α |
| KEYWORDS： | Tobramycin dexamethasone； Meibomian gland dysfunction； Therapeutic efficacy； Safety； IL-6； TNF-α |
| 阅读数： | 461 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
